This undated photo issued by the University of Oxford shows of vial of coronavirus vaccine developed by AstraZeneca and Oxford University, in Oxford, England. Pharmaceutical company AstraZeneca said Monday Nov. 23, 2020, that late-stage trials showed its coronavirus vaccine was up to 90% effective, giving public health officials hope they may soon have access to a vaccine that is cheaper and easier to distribute than some of its rivals. (University of Oxford/John Cairns via AP)

This undated photo issued by the University of Oxford shows of vial of coronavirus vaccine developed by AstraZeneca and Oxford University, in Oxford, England. Pharmaceutical company AstraZeneca said Monday Nov. 23, 2020, that late-stage trials showed its coronavirus vaccine was up to 90% effective, giving public health officials hope they may soon have access to a vaccine that is cheaper and easier to distribute than some of its rivals. (University of Oxford/John Cairns via AP)

VIDEO: How do the leading COVID vaccines differ? And what does that mean for Canada?

All three of the drug companies are incorporating novel techniques in developing their vaccines

On Monday AstraZeneca became the third pharmaceutical company this month to announce promising results from a late-stage coronavirus vaccine clinical trial, joining Pfizer and Moderna as the leading candidates for developing an effective prevention for COVID-19.

While all promise a suitable vaccine can be rolled out within the coming months, they differ slightly in efficacy, delivery and other components.

So how do we judge the leading candidates so far, and how might they impact a vaccine rollout program in Canada?

The Canadian Press asked Kelly Grindrod, an associate professor at the University of Waterloo’s School of Pharmacy, and Dr. Earl Brown, a virology and microbiology expert at the University of Ottawa, to break down those questions.

HOW DO THEY WORK?

All three of the drug companies are incorporating novel techniques in developing their vaccines, with Pfizer and Moderna using messenger RNA (mRNA) and AstraZeneca using a non-replicating viral vector.

AstraZeneca’s vaccine, developed with Oxford University, takes a chimpanzee cold virus that’s not harmful to humans and “hides” pieces of the coronavirus in it, Grindrod explained. Non-replicating means the virus won’t actually reproduce throughout the body.

“It shows our cells how to make the coronavirus spike protein so that our bodies can actually have an immune response to it,” she said.

Brown explained it as a “dummy virus” that has essentially had its genes stripped and replaced with the spike protein gene for the coronavirus. The vaccine makes an mRNA molecule from the genome and that molecule makes the protein, he said.

“The protein is put on the cell, the immune system recognizes it and makes antibodies — therefore immunity.”

The mRNA vaccines are similar, but structurally different with Brown simplifying it by saying Pfizer and Moderna “put the RNA right into your arm.”

“Their vaccine is a synthetically-produced mRNA packaged in a fat coating,” he said. “So they inject that into your muscles, that little fat gloms onto your cells, fuses with them and becomes part of the cell and dumps that mRNA into your cell. And then the mRNA is translated into protein.”

Grindrod said both vaccine methods “show us the genetic component” our cells need to make the antibodies.

“It’s just really how it’s delivered,” she added.

HOW EFFECTIVE ARE THEY?

AstraZeneca says its vaccine was up to 90 per cent effective when a half dose was followed by a full dose a month later. Another method, where two full doses were distributed a month apart, showed to be 62 per cent effective.

Moderna said last week that preliminary data showed a 94.5 per cent efficacy, and Pfizer, the first to share its initial results earlier this month, upped theirs from 90 to 95 after releasing final trial results last week.

While the medical journal “The Lancet” did review some of AstraZeneca’s results, Grindrod says to remember that most of the efficacy claims from the clinical trials are from press releases based off preliminary data.

“Now what we’re waiting for is the actual study, the full published, peer review that you can see and compare efficacy and safety and how they measured it,” she said, adding she expects peer-reviewed studies on the vaccines to emerge soon.

“Things are coming at much different timelines than we’re used to.”

Another factor that’s still unknown is how long immunity lasts, and whether we will need booster vaccines in the future.

WHAT ARE THE HURDLES FACING DISTRIBUTION?

All three of the leading vaccine candidates require two doses, injected roughly one month apart, and there could be challenges in getting people back to a doctor or pharmacy to receive their second dose.

Grindrod said tracking will become particularly important with a two-dose vaccine, especially if AstraZeneca goes forward with injecting different amounts of the vaccine per dose. Rollout can become even more complicated when there’s a surge for the vaccine, as we saw this year with the flu shot.

“You have to track who got which vaccine, which dose, and make sure they come back three to four weeks later,” she said.

Where AstraZeneca could have the upper hand in distribution, however, is in its storage temperature. The company says its vaccine can be stored in a fridge, unlike Moderna and Pfizer, which require freezing temperatures due to the instability of the mRNA, Brown says.

Pfizer’s vaccine needs to be stored at minus-70 C, while Moderna’s needs a temperature around minus-20 C — about the same as a regular freezer.

“For really ultra-low temperature freezers, you find those in hospitals and research laboratories, but not many other places,” Brown said. “So we aren’t prepared for (a vaccine that requires) ultra low freezers.”

READ MORE: 3rd major COVID-19 vaccine shown to be effective and cheaper

ARE THERE ANY SIDE EFFECTS?

Side effects for all three vaccines have been minimal — things like sore arms, fatigue and headaches that generally don’t last long — and Brown says the presence of those reactions are a good thing.

“When you’re vaccinating, you’re stimulating an immune response, and those are immune-regulated things,” he said. “So a sore arm reaction is good, because that means it’s working for you.”

More safety data, which can only be garnered from monitoring trial participants over a longer term, is needed to judge further, he says.

WHAT’S NEXT, AND WHAT DOES IT MEAN FOR CANADA?

The Food and Drug Administration (FDA) is meeting to discuss Pfizer’s emergency use authorization request on Dec. 10, which means a vaccine rollout could happen in the United States within the next month.

But the vaccines would need approval from Health Canada in order to get them here.

Health Canada’s website says it will review authorization submissions from companies to determine “evidence of safety, efficacy and manufacturing quality for each vaccine.”

Canada locked in a supply of potential vaccine candidates when it signed agreements with a number of pharmaceutical companies, including AstraZeneca, Pfizer and Moderna months ago, and that should accelerate a rollout when ready.

READ MORE: First COVID vaccines could arrive in U.S. on Dec. 12

But the actual time frame will depend on when these drug companies can show enough safety data to move forward, Brown said.

Grindrod expects a viable candidate to be approved quickly after safety and efficacy can be shown.

“We might see early 2021 and it’s not clear whether that’s January or February or around that time,” she said. “From there, as we get more doses and more vaccines are approved, then we may see a broader population getting vaccinated. But it’s hard to say when that will happen.”

Melissa Couto Zuber, The Canadian Press


Like us on Facebook and follow us on Twitter.

Want to support local journalism during the pandemic? Make a donation here.

Coronavirusvideo

Get local stories you won't find anywhere else right to your inbox.
Sign up here

Just Posted

The Abbotsford board of education said on Tuesday they are satisfied with how students and staff dealt with the COVID-19 pandemic from September to December.
Abbotsford board of education pleased with return to class during COVID-19

District officials thank staff and students for low number of infections and issues during pandemic

The route of the pink parade. The Record has blackened out the name of the teen. Facebook photo.
Pink-vehicle parade to be held Sunday in support of transgender teen assaulted in Mission

Teen and family to watch parade drive single file along waterfront at 3 p.m., Jan. 17

Abbotsford’s Conair Group Inc. made a big purchase recently to continue creating new firefighter airtankers. (Submitted)
Abbotsford’s Conair expanding fleet of firefighting airtankers

Local group creating new Q400AT planes to fight wildfires across the globe

Letisha Reimer died Nov. 1, 2016 after being stabbed at Abbotsford Senior Secondary.
No evidence that killer was in ‘psychotic state’ during Abbotsford school stabbing: Crown

Second day of closing arguments at ‘not criminally responsible’ hearing for Gabriel Klein

Wind takes down power lines in Abbosford. (Amanda B. Macchioni photo)
SLIDESHOW: Abbotsford wind storm pictures

User submitted images of the aftermath following Tuesday’s storm

A woman wears a face mask and shield to curb the spread of COVID-19 while walking in North Vancouver, B.C., on Wednesday, January 6, 2020. THE CANADIAN PRESS/Darryl Dyck
536 COVID cases, 7 deaths reported as B.C. finds its first case of South African variant

Henry said 69,746 people have received their first dose of the COVID vaccine.

A northern resident killer whale shows injuries sustained by a collision with a vessel in B.C. waters. (Photo supplied by Ocean Wise Conservation Association)
Coast Guard ramps up protections for B.C. whales

First-ever Marine Mammal Desk will enhance cetacean reporting and enforcement

Two toucans sit on tree at an unidentified zoo. (Pixabay.com)
BC SPCA calls for ban on exotic animal trade after 50 parrots, toucans pass through YVR

One toucan was found dead and several others were without food

Prime Minister Justin Trudeau listens to a question during a news conference outside Rideau cottage in Ottawa, Friday, January 8, 2021. THE CANADIAN PRESS/Adrian Wyld
Trudeau says Canada’s COVID vaccine plan on track despite Pfizer cutting back deliveries

Canadian officials says it will still likely receive four million doses by the end of March

Alan Davidson was sentenced to almost six years for abusing seven boys in the late 1970s and early 1990s. (Canadian Press file)
Full parole granted to former Mountie, sports coach convicted of sex abuse of boys

Alan Davidson convicted of abusing boys in B.C. and Saskatchewan in late ’70s, early ’90s

The first COVID-19 vaccine arrives in B.C. in temperature-controlled containers, Dec. 13, 2020. (B.C. government)
More vaccine arrives as B.C. struggles with remote COVID-19 cases

Long-term care homes remain focus for public health

Cannabis bought in British Columbia (Ashley Wadhwani/Black Press Media)
Is it time to start thinking about greener ways to package cannabis?

Packaging suppliers are still figuring eco-friendly and affordable packaging options that fit the mandates of Cannabis Regulations

The first Pfizer-BioNTech COVID-19 vaccine dose in Canada is prepared at The Michener Institute in Toronto on Monday, Dec. 14, 2020. THE CANADIAN PRESS/Frank Gunn
Doses of COVID-19 vaccine expected in 60 B.C. First Nations by next week

B.C. has allocated 25,000 doses of COVID-19 vaccine to First Nations for distribution by the end of February

Most Read